GHK-Cu

Best-evidenced of the wellness peptides for skin: GHK-Cu delivers copper and shifted the expression of roughly a third of human genes in a database analysis of cultured cells (a lab finding, not a human outcome), stimulating collagen, dampening inflammation, acting as an antioxidant. Strong in cell and topical studies; injectable effects extrapolate from there.

Result tags: the skin and wound claims are graded by the randomized post-laser trial. Higher satisfaction was reported, objective redness and wrinkle measures did not differ, and the tag shows that split.

Adverse events

Topical use is well-established and benign. Injectable adverse events are poorly characterized simply because injectable human use is new.

Contraindications

Wilson's disease or copper-overload conditions (copper content). Caution with injectable use given thin data.

Theoretical concerns

Copper toxicity is a theoretical concern at high injected doses; topical exposure is far below that threshold.

What nobody knows yet

Long-term injectable safety, and whether injectable efficacy matches the well-documented topical effect.

What else could explain the result

Skin improvement is heavily confounded, retinoids, sunscreen, red light, microneedling, hydration and sleep all move the same needle. GHK-Cu users typically run several of these at once.

Is the vial what it says?

For topical, a straightforward COA confirming GHK-Cu identity and concentration is enough. For injectable, apply the full standard. HPLC ≥98%, mass-spec identity, LAL endotoxin from an independent third-party lab, and verify copper content is within spec, since the chelated copper is both the active and the hazard.

Half-life and storage

Half-life: Short in the bloodstream; applied topically it acts locally over hours. Injectable human pharmacokinetics are not well characterized.

Once mixed: The copper complex is both the active and the hazard, store cold and protected from light. Topical serums are more shelf-stable than a reconstituted injectable, where copper content needs to stay in spec.

Case study

• GHK-Cu: I inject it, and our own grade says the evidence is for skin RunningI run the injectable for one reason, healing after a skin laser, and I watch the copper because of it.

What people report

Volume of reports: mixed. Reports exist but contradict each other.

Large for topical skincare; a smaller, more honest injectable community.

Topical firmness/texture reports converge, but there's a real negative cluster (the 'copper uglies') and injectable is quieter.

Among the most influencer-contaminated spaces; the credible signal lands on 'useful supporting ingredient, not a miracle.'

• Topical skin and hair improvement is widely and consistently reported, the best-substantiated of any wellness peptide here.
• Injectable users report skin, hair, and recovery benefits, but the record is much thinner.
• Well-tolerated topically; injectable site irritation is occasionally reported.

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: Discovered in 1973 by Dr. Loren Pickart, who identified GHK in human plasma and demonstrated its activity in human tissue studies. Topical human use is well-documented; injectable human use is recent and sparse.

1. 1973Dr. Loren Pickart discovers GHK in human plasma.
2. 1980s-2010sGHK-Cu becomes a staple of cosmetic skincare; hundreds of topical studies accumulate.
3. 2006Randomized post-laser study (13 completers) finds higher patient satisfaction with GHK-Cu but no objective gain in redness or wrinkles.
4. Sept 2023FDA prohibits injectable GHK-Cu for commercial compounding (Category 2).
5. Apr 22 2026FDA drops injectable GHK-Cu from its Category 2 list after the nominators withdrew it. That is not permission to compound it; FDA plans an advisory meeting before the end of February 2027.
6. May 14 2026The non-injectable form, which left Category 1 on April 22, is added back to Category 1 after one nominator said it had meant to withdraw only the injectable route.

• Mateescu et al. 2026, GHK-Cu evidence-mapping review (Pharmaceutics)
• Miller et al. 2006, post-laser RCT
• Huang et al. 2007 (Photomed Laser Surg), in vitro
• Pickart & Margolina 2018, foundational GHK-Cu review
• Bo SL, Nararatwanchai T, et al. Randomized, double-blind, vehicle-controlled split-face study, Mae Fah Luang University M.Sc. thesis (2025), later published as Procedia Multidiscip Res 2026;4:16; listed in Mateescu et al. 2026, Pharmaceutics 18(9):1077, PMID 42797253 (PMC13610439)(dose table)
• Miller TR, Wagner JD, Baack BR, Eisbach KJ. Arch Facial Plast Surg 2006;8(4):252-259. doi:10.1001/archfaci.8.4.252. PMID 16847171(dose table)
• Huberman Lab episode with Dr. Abud Bakri, chapters 01:50:33 (GHK-Cu, collagen) and 02:15:36 (GHK-Cu, topical cream, red light); read from the episode transcript(dose table)